Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Read more about Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Read more about Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Revisiting RECIST: the case of treatment beyond progression. Read more about Revisiting RECIST: the case of treatment beyond progression.
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Read more about Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.
Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Read more about Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply. Read more about Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.
Future cancer research priorities in the USA: a Lancet Oncology Commission. Read more about Future cancer research priorities in the USA: a Lancet Oncology Commission.
Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer. Read more about Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer.
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Read more about Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Increasing global access to cancer care: models of care with non-oncologists as primary providers. Read more about Increasing global access to cancer care: models of care with non-oncologists as primary providers.
